Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription 17.08.2026 2 Am J Hematol 1 Blood 1 BMC Cancer 4 Br J Haematol 1 J Clin Oncol 1 Leuk Lymphoma 1 Mod Pathol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. SONG Y
   Current Treatment Landscape and Advances in Lymphoma in China: A Special Issue.
   Am J Hematol. 2026 Aug 13. doi: 10.1002/ajh.70471.
   PubMed        
   
   
2. ZHAO P, Wang Y, Bai M, Huang C, et al
   Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.
   Am J Hematol. 2026 Aug 13. doi: 10.1002/ajh.70456.
   PubMed         Abstract available
   
   

   
   Blood

3. 
   Abro B, Maurer MJ, Habermann TM, et al. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. Blood. 2024;144(19):2063-2066.
   Blood. 2026;148:914.
   PubMed        
   
   

   
   BMC Cancer

4. TILCH MK, Schmidt C, Trneny M, Gine E, et al
   Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after a
   BMC Cancer. 2026;26:964.
   PubMed         Abstract available
   
   

   
   Br J Haematol

5. GUI J, Yang A, Lin J, Che Q, et al
   Pathway alteration burden derived from whole-exome sequencing is associated with survival in primary central nervous system lymphoma.
   Br J Haematol. 2026 Aug 15. doi: 10.1111/bjh.70734.
   PubMed         Abstract available
   
   
6. WINSA A, Lagerlof I, Ellin F, Fredriksson M, et al
   The association between inborn errors of immunity and Hodgkin lymphoma-A register-based case-control study in Sweden.
   Br J Haematol. 2026 Aug 12. doi: 10.1111/bjh.70743.
   PubMed         Abstract available
   
   
7. PAVLOVSKY A, Fiad L, Fernandez I, Prates V, et al
   Long-term follow-up of PET/CT-adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH-05 trial.
   Br J Haematol. 2026 Aug 9. doi: 10.1111/bjh.70721.
   PubMed         Abstract available
   
   
8. MUNKSGAARD L, Pedersen LM, Gjerdrum LMR
   Second primary cancers in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia-cumulative burden without generalized excess cancer risk.
   Br J Haematol. 2026 Aug 9. doi: 10.1111/bjh.70740.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. LYNCH RC, Poh C, Shadman M, Till BG, et al
   Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
   J Clin Oncol. 2026 Aug 14:JCO2502906. doi: 10.1200/JCO-25-02906.
   PubMed         Abstract available
   
   

   
   Leuk Lymphoma

10. WANG C, Liang Y, Liu X, Zeng L, et al
    Effects of O-GlcNAc glycosylated modified transferase on prognosis of diffuse large B-cell lymphoma and analysis of downstream targets.
    Leuk Lymphoma. 2026 Aug 13:1-26. doi: 10.1080/10428194.2026.2712107.
    PubMed         Abstract available
    
    

    
    Mod Pathol

11. EREM AS, Pepin N, Sacknovitz Y, Kent JA, et al
    Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.
    Mod Pathol. 2026 Aug 13:101054. doi: 10.1016/j.modpat.2026.101054.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum